Value of medicines optimisation within the new ICB structures and systems
MO affects most business of the new ICB with its strategic priorities needing to be enacted through contracting and commissioning if England is to retain any control of its prescribing liabilities and quality/safety oversight.
- Levers for enacting MO priorities New roles for MO Medical expertise and how to use it in the new world.

